Related and Nonrelated Parties [Axis] Sanovas Ophthalmology LLC [Member] Related Party [Member] Class of Stock [Axis] Series F Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exchange Agreement [Member] Business Acquisition [Axis] DNA/GPS Inc [Member] Statement of Income Location, Balance [Axis] In Process Research and Development [Member] Vendor [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Pre-funded Warrant [Member] Warrant [Member] Title and Position [Axis] Officer [Member] Halo Management LLC [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Plan Name [Axis] 2017 Equity Incentive Plan [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Stock Option One [Member] Stock Option Two [Member] Jerry Katzman MD [Member] Virender Ahluwalia [Member] Herbert Gould MD [Member] Dessy Boneva MD [Member] Vinay Mehindru MD [Member] Warrant One [Member] Warrant Two [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Share Price [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current Assets Cash Total Current Assets Equipment, net of accumulated depreciation of $176 and $151 TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities Current Liabilities Accounts payable and accrued liabilities Due to related parties Shareholders’ notes payable Accrued interest payable Total Liabilities Stockholders’ Deficit: Preferred stock, $0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at December 31, 2023 and March 31, 2024 Common stock, $0.0001 par value; 80,000,000 shares authorized; 17,860,478 and 17,635,478 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Additional paid in capital Accumulated deficit Total Stockholders’ Deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Statement [Table] Statement [Line Items] Accumulated depreciation Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating expenses: General and administrative expenses Research and development Stock-based compensation Total Operating expenses Interest expense Net loss Net loss per share, basic Net loss per share, diluted Weighted average number of common shares outstanding during the period- basic Weighted average number of common shares outstanding during the period- diluted Balance Balance, shares Stock based compensation Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares Net loss Exercise of stock options Exercise of stock options, shares Settlement of accounts payable with shares Settlement of accounts payable with shares, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows From (Used In) Operating Activities Adjustments to reconcile net loss to net cash used in operating activities Non-cash items: Stock based compensation expense Depreciation expense Expenses paid by Sanovas on behalf of Company, net Changes in operating assets and liabilities: Increase in accounts payable and accrued liabilities Increase in accrued interest Total Adjustments Net cash used in operating activities Cash Flows From (Used In) Financing Activities Proceeds from stock options exercised Advances from related parties Net cash provided by financing activities Net increase in cash Cash at beginning of period Cash at end of period Supplemental information: Settlement of accounts payable with issuance of shares Accounting Policies [Abstract] HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] COMMON AND PREFERRED STOCK STOCK PLAN Warrants WARRANTS Debt Disclosure [Abstract] SHAREHOLDERS’ NOTES PAYABLE Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Cash Equivalents Use of Estimates Income Taxes Income (Loss) Per Common Share Stock-based compensation: Research and Development costs: Property and Equipment: Recent Accounting Pronouncements: SCHEDULE OF RELATED PARTY TRANSACTIONS SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF WARRANTS OUTSTANDING SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Shares issued for acquisitions Estimated fair value of transaction Legal fees Accumulated deficit Liabilities Other liabilities Issuance of shares Payment of expenses Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share Property and equipment useful life Related Party Transaction [Table] Related Party Transaction [Line Items] Balance due to (from) Sanovas – beginning of year Costs paid by Sanovas on the Company’s behalf Costs of Sanovas allocated to the Company Proceeds from (repayment of) costs charged by Sanovas to the Company, net Balance due to Sanovas - end of period Related party cost Advance funds received Stock, Class of Stock [Table] Class of Stock [Line Items] Issuance of shares of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Settlement of of accounts payable Issuance of stock option were exercised Stock option exercised for cash payment Preferred stock, voting right Preferred stock, protective features Preferred stock, dividend Preferred stock conversion basis Preferred stock conversion terms Proceeds from issuance of preferred stock Options Issued, Options outstanding, beginning balance Weighted-Average Exercise Price, Options outstanding beginning balance Options Issued, Granted Weighted-Average Exercise Price, Granted Options Issued, Canceled Options Issued, Forfeited Weighted-Average Exercise Price, Forfeited Options Issued, Exercised Weighted-Average Exercise Price, Canceled Weighted-Average Exercise Price, Exercised Options Issued, Options outstanding, beginning balance Weighted-Average Exercise Price, Options outstanding ending balance Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Exercise Price Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable Risk-free interest rates Expected life in years Expected volatility Expected dividend yield Fair value common stock Common stock shares reserved for future issuance Stock option expense Unrecognized compensation expense Weighted-average period for recognition Shares available for issuance Fair value of option grant price per share Fair value of option grant price per share Schedule Of Warrants Activity Warrants Issued, Warrants outstanding, beginning balance Weighted-Average Exercise Price, Warrants outstanding, beginning balance Warrants Issued, Granted Warrants Issued, Canceled Warrants Issued, Exercised Weighted-Average Exercise Price, Granted Weighted-Average Exercise Price, Canceled Weighted-Average Exercise Price, Exercised Warrants Issued, Warrants outstanding, ending balance Weighted-Average Exercise Price, Warrants outstanding, ending balance Exercise Price Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrant measurement input Expected life in years Warrant exercise price Warrant vesting, term Warrant shares Stock-based compensation expense Common stock exchanged for warrants Warrant issued to purchase common stock Debt instrument, face amount Interest rate Maturity date Extended maturity date Proceeds from exercise of warrants Notes payable Interest expense Accrued interest Costs of related party allocated. Sanovas Ophthalmology LLC [Member]. Halo Management LLC [Member] 2017 Equity Incentive Plan [Member]. Stock Option One [Member] Stock Option Two [Member] Jerry Katzman MD [Member] Virender Ahluwalia [Member] Herbert Gould MD [Member] Dessy Boneva MD [Member] Vinay Mehindru MD [Member] Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price granted. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price cancelled. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price exercised. Schedule Of Warrant Outstanding [Table Text Block] Warrant One [Member] Warrant Two [Member] Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual terms. Share based compensation arrangement by share based payment award non option equity instruments exercisableNumber. Exchange Agreement [Member] Pre-funded Warrant [Member] Settlement of accounts payable with issuance of shares. DNA/GPS Inc [Member] Acquired In-process research and development through issuance of common stock. Vendor [Member] Warrants Disclosure [Text Block] Schedule of share based payment award warrants valuation assumptions. Share based Compensation Arrangement By Share based Payment Award Warrant Fair Value Assumptions Expected Term 1. Extended maturity date. Assets, Current Assets Liabilities [Default Label] Equity, Attributable to Parent Liabilities and Equity Operating Expenses Shares, Outstanding Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Proceeds from (Repayments of) Related Party Debt Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantFairValueAssumptionsExpectedTerm1 Interest Expense, Debt